{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004106","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.700579+00:00","generated_at":"2026-06-19T03:14:00.602697+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relay Therapeutics reports Q4 2022 net loss of $67.5M; cash ~$1B funds into 2025","bullets":["Net loss per share $0.56 for Q4 2022, flat vs Q4 2021; full-year net loss $290.5M ($2.59/share).","Cash, cash equivalents and investments ~$1.0B as of Dec 31, 2022, up from $958.1M year-end 2021.","RLY-4008 interim data: 88% ORR at pivotal dose (70 mg) in FGFR2-fusion cholangiocarcinoma; registrational path set.","Breast cancer portfolio: RLY-2608 monotherapy and combination arms ongoing; initial data expected H1 2023.","Raised $300M gross proceeds in follow-on public offering; R&D expenses $246.4M for full year 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004106","json":"https://secwatch.observer/filing/0000950170-23-004106.json","markdown":"https://secwatch.observer/filing/0000950170-23-004106.md","text":"https://secwatch.observer/filing/0000950170-23-004106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/0000950170-23-004106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/rlay-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:14:00.602697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6470858ec5e0b7f0f4ecc6701d86e3eba6151901","claim":"Relay Therapeutics, Inc. reported the fourth quarter of 2022 results: net income $67.5 million, EPS $0.56.","evidence_excerpt":"Net loss was $67.5 million for the fourth quarter of 2022, or a net loss per share of $0.56","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/0000950170-23-004106-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Net income","value":"$67.5 million"},{"label":"EPS","value":"$0.56"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c1c4e5208be9bfc6b2712f339aa6881ac47b67f2","claim":"Relay Therapeutics, Inc. reported financial results for the full year 2022.","evidence_excerpt":"On February 23, 2023, Relay Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/0000950170-23-004106-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}